YourChoice Therapeutics
YC W19 ↗San Francisco, US · 3 employees · 4 known investors
YourChoice Therapeutics develops YCT-529, a non-hormonal oral contraceptive for men currently in Phase 2 clinical trials that works by blocking a receptor essential for sperm production. The company targets men seeking an alternative to condoms or vasectomy.
Founders & leadership· Y Combinator alumni (W19)
Investors · 4
In the news
- YourChoice’s non-hormonal male birth control is safe so farfiercebiotech.com · 2024
- Male Birth Control Pill Enters Clinical Trialsfstandard.com · 2023
- YourChoice Therapeutics Begins Landmark Trial for Hormone-Free Male Birth Control Pillfemtechinsider.com · 2023
- Male birth control pill enters Phase 1 trial in U.K.statnews.com · 2023
- Male Contraception Company YourChoice Therapeutics Adds $15M in Series A Funding to Kick Off Human Trials | Femtech Insiderfemtechinsider.com · 2022
- YourChoice Therapeutics raises $15M Series A for male birth controlaxios.com · 2022
- YourChoice Therapeutics | Goldengolden.com
- YourChoice Therapeutics 7/21/2022 Capital Raise - Gaebler.com Venture Capital Databasegaebler.com